drugset / Trial / NCT00082914
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Open-labelTreatment
Summary
RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma or metastatic kidney cancer.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin diftitox | Protein / enzyme biologic | — | Intravenous |